ClinicalTrials.gg
RecruitingNCT06611306BEAT-BreastUpdated Oct 8, 2026

BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.

An interventional study of DE-iPTV in Brain Metastases, Adult and Breast Cancer, sponsored by Imperial College London. Recruiting at 2 sites in United Kingdom. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Imperial College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 8, 2026Now RecruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
16 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Brain Neoplasms with a site in United Kingdom — 18 open to participants now, 29 under way, 5 of them phase 3. Brain Neoplasms · United Kingdom.

Planned enrollment
52nd of 72
42 · median 120
Started
2026
with 3 others
No phase
15 of 88
6 open now
Primary completion
2027-12
later than 18 of 28 live
Registered
83rd of 88
by date
Lead sponsor
2 of 88
Imperial College London

Among the 88 studies in Brain Neoplasms with a site in United Kingdom, this one is the 52nd largest by planned enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2026, is one of 15 with no phase, reaches primary completion later than 18 of the 28 other live ones, and was the 83rd registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

18 of the 88 studies in Brain Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 16 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Brain Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast cancer has spread to the brain (brain metastases) at 8 weeks post enrolling into the study.

The main questions that have been set out to to answer are:

  • Is it possible to deliver the novel radiotherapy approach, DE-iPTV?
  • Is it possible to measure health -related quality of life?
  • What impact does the novel radiotherapy approach have on: patient's quality of life, control of the brain metastasis (control of the lesion) and steroid use?

Participants will:

  • Receive 5 doses of radiotherapy
  • Complete weekly quality of life (EQ-5D) assessments and medication (steroid) diaries (via telephone/ postal) until 12 weeks post enrolment
  • Be reviewed in clinic with up-to-date MRI scans at 8, 12 and 24 weeks post-enrolment
  • Complete a more detailed HRQoL panel of assessments will be assessed at baseline, 8 weeks, 12 weeks and 24 weeks post enrolment.
Read the detailed description

Brain metastases from breast cancer are a common, and devastating, complication with survival times of 3 - 5 months from diagnosis.

The main treatment approaches to brain metastases are surgery, stereotactic radiosurgery (SRS), and whole brain radiotherapy. However, it is known that most patients with brain metastases receive either whole-brain radiotherapy (WBRT) or no treatment, with relatively low rates of surgery and SRS. Since the commonest treatment in those who do have treatment is WBRT, the local team have developed an approach that is believed to be (possibly) more effective than WBRT. The objective is to evaluate this approach in patients who are not suitable to receive more aggressive treatment and who would otherwise receive WBRT. The local approach involves using a modern radiotherapy planning approach, combined with careful, intra-metastasis dose escalation (Dose Escalated internal PTV (DE-iPTV)) to deliver a higher dose to tumour, while delivering less dose to the brain. The combination of less dose to normal structures and more dose to the lesion will hopefully improve Health-related Quality of Life (HRQoL).

The aim of this study is to demonstrate the feasibility of delivering complex radiotherapy, dose escalated internal PTV (DE-iPTV), and measuring quality of life at 8 weeks post-enrolment for patients with brain metastases from breast cancer who would otherwise receive WBRT. An exploratory blood-based biomarker sample collection and analysis will be completed. Furthermore, linked national cancer data will be used to measure the number of patients currently offered WBRT, including survival costs and hospital admissions, and thus provide a baseline to estimate the impact of this novel approach.

03

Conditions studied

  • Brain Metastases, Adult
  • Breast Cancer

Keywords

  • Radiotherapy
  • Brain metastases
  • Metastatic Breast Cancer
04

Who can participate

Ages eligible
16 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written (signed and dated) and be capable of co-operating with treatment and follow-up
  2. Adult (aged 16+) patients, resident in the United Kingdom.
  3. confirmed primary breast cancer with on MRI imaging
  4. The treating oncologist considers whole-brain radiotherapy to be the most suitable treatment outside of the trial.
  5. Performance status 0, 1 or 2
  6. Able to respond to question about their quality of life, symptoms, and side effects remotely (via telephone assessments
  7. from extra-cranial disease >3 months

Exclusion criteria

Exclusion Criteria

  1. "Miliary" pattern of : patients with over 15 metastases are excluded (clinician-based assessment)
  2. Cystic metastases
  3. Previous whole or partial brain radiotherapy (previous surgery or SRS is acceptable)
  4. Plan for hippocampal-sparing whole brain radiotherapy.
  5. Unable to give .
  6. Prognosis less than 3 months
  7. Pregnant or nursing women
  8. Unable to complete a brain MRI and/or known allergy to gadolinium.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    DE-iPTV radiotherapy

    Patients will undergo a radiotherapy planning scan, and an upto date MRI brain with contrast. Patients will receive 5 fractions of DE-iPTV radiotherapy over 1 week.

    Radiation: DE-iPTV

Interventions

  • RadiationDE-iPTV

    Dose-escalated VMAT-based radiotherapy, as previously described in our planning study

06

What researchers measure

Primary outcomes

  1. Feasibility of delivering DE-iPTV and measuring health related quality of life questionnaire in patients with brain metastases from breast cancer to whom their treating clinician would normally offer whole brain radiotherapy

    Completion of radiotherapy and completion of EuroQol- 5 Dimension (EQ-5D-5L) questionnaire

    Time frame: 8 weeks post-enrolment

Secondary outcomes

  1. Lesional Response

    Lesional response and intracranial progression measured using RANO-BM criteria

    Time frame: 8 weeks

  2. Intracranial progression

    Intracranial progression based on RANO-BM

    Time frame: 3 months

  3. Intracranial progression

    Intracranial progression based on RANO-BM

    Time frame: 6 months

  4. Treatments

    Use of further brain-directed therapies (reported by clinician)

    Time frame: Within 6 months of enrolment

  5. Central Nervous System (CNS) Failures

    Time to CNS failure (either lesional progression or developing a new lesion as per RANO-BM)

    Time frame: Within 6 months of enrolment

  6. Neurological toxicities

    Acute and late neurological/ CNS toxicity as assessed using CTCAE v5

    Time frame: Within 6 months of enrolment

  7. Health Related Quality of Life

    HRQoL over time (participants reported outcomes for descriptive analysis)

    Time frame: Within 6 months of enrolment

  8. Time to deterioration in quality of life

    Time to deterioration in Health Related Quality of Life - measured as time to first time there is a minimum clinically significant change in EuroQol- 5 Dimension (EQ-5D-5L)

    Time frame: Within 6 months of enrolment

  9. Symptom Burden

    Symptom burden assessed by collection of clinician-recorded toxicities

    Time frame: Within 6 months of enrolment

  10. Steroid usage

    Use of corticosteroids over time, assessed through clinician reports and patient diaries

    Time frame: Within 6 months of enrolment

  11. Quality-Adjusted Life Year

    Quality-Adjusted Life Year

    Time frame: Within 6 months of enrolment

  12. Overall survival

    Overall survival

    Time frame: End of study

Other outcomes

  1. Changes in blood-based biomarkers

    Change between baseline and week 8 levels of Circulating Tumour DNA (ctDNA) and S100

    Time frame: 8 weeks

  2. Imaging Changes

    MRI-based response (as per RANO-BM and serial volumetric measurements)

    Time frame: Up to 6 months post enrolment

  3. Radiation Necrosis

    Radiation necrosis based on radiologist report

    Time frame: Up to 6 months post enrolment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Chen J, Sinclair G, Rozati H, Hill L, Pakzad-Shahabi L, Wang J, Calvez KL, Paddick I, Williams M. Improving on whole-brain radiotherapy in patients with large brain metastases: A planning study to support the AROMA clinical trial. Radiother Oncol. 2022 May;170:176-183. doi: 10.1016/j.radonc.2022.02.011. Epub 2022 Feb 17. PubMed 35182688 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 18 months is below that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Jan 2025 → Jun 2026, primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 24, 2024
StartActual
Jun 1, 2026was Jan 2025
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Jun 2028was Dec 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
2 sites added, 1 site removed
Show 2 added (2 United Kingdom)
  • Imperial College London · London, United Kingdom
  • University of Oxford Cancer and Haematology Centre | Churchill Hospital Headington, Oxford, · Oxford, United Kingdom
Show 1 removed
  • Imperial College London · London, United Kingdom
Oct 8, 2026
Start date
Jan 6, 2025→Jun 1, 2026 (actual)
Oct 8, 2026
Primary completion
Dec 2026→Dec 2027
Oct 8, 2026
Study completion
Dec 2026→Jun 2028
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    2 sites added, 1 site removed
    Show 2 added (2 United Kingdom)
    • Imperial College London · London, United Kingdom
    • University of Oxford Cancer and Haematology Centre | Churchill Hospital Headington, Oxford, · Oxford, United Kingdom
    Show 1 removed
    • Imperial College London · London, United Kingdom
    Start date Jan 6, 2025→Jun 1, 2026 (now actual)
    Primary completion Dec 2026→Dec 2027
    Study completion Dec 2026→Jun 2028
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06611306
Collaborators
University of Leicester, Centro Nacional de Investigaciones Oncologicas CARLOS III, East and North Hertfordshire NHS Trust, Norfolk and Norwich University Hospitals NHS Foundation Trust, Imperial College Healthcare NHS Trust
Responsible party
Sponsor
First posted
Sep 24, 2024
Start date
Jun 1, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Lillie Pakzad-Shahabi, BSc MSc
Contact
beat-breast@imperial.ac.uk
02033118427
Matt Williams, FRCR PhD
Contact
matthew.williams@imperial.ac.uk
02033118427

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion